z-logo
open-access-imgOpen Access
Repeated dermal application of the common preservative methylisothiazolinone triggers local inflammation, T cell influx, and prolonged mast cell-dependent tactile sensitivity in mice
Author(s) -
Jessica Kline,
Erica Arriaga-Gomez,
Tenzin Yangdon,
Beebie Boo,
Jasmine Landry,
Marietta Saldías-Montivero,
Nefeli Neamonitaki,
Hanna Mengistu,
Sayira Silverio,
Hayley Zacheis,
Dogukan Pasha,
Tijana Martinov,
Brian T. Fife,
Devavani Chatterjea
Publication year - 2020
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0241218
Subject(s) - mast cell , medicine , inflammation , degranulation , immunology , allergy , cd8 , immune system , receptor
Occupational exposure to toxic chemicals increases the risk of developing localized provoked vulvodynia—a prevalent, yet poorly understood, chronic condition characterized by sensitivity to touch and pressure, and accumulation of mast cells in painful tissues. Here, we topically sensitized female ND4 Swiss mice to the common household and industrial preservative methylisothiazolinone (MI) and subsequently challenged them daily with MI or acetone and olive oil vehicle on the labiar skin. MI-challenged mice developed significant, persistent tactile sensitivity and long-lasting local accumulation of mast cells alongside early, transient increases in CD4 + and CD8 + T cells, eosinophils, neutrophils, and increases in pro-inflammatory cytokines. Therapeutic administration of imatinib, a c-Kit inhibitor known to inhibit mast cell survival, led to reduced mast cell accumulation and alleviated tactile genital pain. We provide the first pre-clinical evidence of dermal MI-induced mast-cell dependent pain and lay the groundwork for detailed understanding of these intersections between MI-driven immunomodulation and chronic pain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here